Methotrexate and psoriasis in the era of new biologic agents
Open Access
- 29 February 2004
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 50 (2), 301-309
- https://doi.org/10.1016/s0190-9622(03)00803-x
Abstract
No abstract availableThis publication has 75 references indexed in Scilit:
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patientsBritish Journal of Dermatology, 1996
- Proceedings of the Psoriasis Combination and Rotation Therapy Conference: Deer Valley, Utah, Oct. 7–9, 1994Journal of the American Academy of Dermatology, 1996
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991
- Cyclosporine and methotrexate: A dangerous combinationJournal of the American Academy of Dermatology, 1990
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritisDigestive Diseases and Sciences, 1985
- Methotrexate guidelines—revisedJournal of the American Academy of Dermatology, 1982